🔗 Share this article

While the US undertakes unprecedented changes to its immunization guidelines, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccines during the global health crisis and has concentrated on potential deaths after COVID-19 vaccination in her short time at the FDA.

Proposed Shifts to Pediatric Immunization Program

Agency leaders had intended to announce sweeping changes to the childhood vaccine schedule recently, aligning the US with Denmark’s national calendar, it is understood – a major change that would put the US at odds with a large portion of the global community with insufficient data for benefit. This reveal has been delayed until the coming year.

In place of the top vaccines chief, Høeg is set to address the audience at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more similar to the Danish model, a society with nationalized medicine and a population approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has no apparent background in drug development, oversight or management, which has been customary for former directors of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “understand legal statutes and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who ran CBER have had.”

CDER has an immense portfolio at the agency, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the generic program clears thousands of generic medications. There’s a biosimilars division, over-the-counter program and more, and all of those need to be managed,” Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership element to the role, which oversees more than 5,000 staff members. “It is a enormous leadership role, if you do it right,” the former official said.

Agency Reaction and Disputed Policies

When asked about questions about Høeg’s qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a spokesperson stated that the “inquiries are based on inaccurate premises”.

“Her experience aligns with the duties of her role,” the representative said, citing the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the agency head's controversial priority voucher program, a contentious expedited drug-approval program that allegedly troubled her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who takes the calls?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of shots.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if troubling, past, critics observe. She published a study using non-validated volunteer-provided data to assess the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current federal leadership featured revising regulations for novel immunizations and halting “non-essential” immunizations, she stated after the election on a online show. At the FDA, Høeg has according to sources proposed barring teenage boys from receiving COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the science in a extremely disingenuous, untruthful fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|